F8 and hemophilia A: While there were only 20 publications included in the review, and inconsistencies and gaps in the reporting of information, this analysis in people with hemophilia A without FVIII inhibitors undergoing surgery is consistent with the previously reported safety profile and efficacy/effectiveness of emicizumab prophylaxis [[9], [10], [11], [12], [13],[15], [16], [17], [18], [19], [20],43].